anonymous
Guest
anonymous
Guest
AbbVie and Alkermes reps have been jumping ship and running to BMS. High bases sound attractive right now but theyre going to get their arses kicked when Emraclidine comes next year. No constipation and qd dosing. BMS doesn’t have time to recoup their $15B.